1
This audio is auto-generated. Please let us know if you have feedback.
Merck & Co.’s presence in cancer has long rotated around its crown jewel checkpoint inhibitor Keytruda. But with the blockbuster approaching a series of patent cliffs, Merck is writing its next chapter in cancer R&D.
“In our prior era, everything was about Keytruda,” Dr. Alex Snyder, the company’s senior vice…